The United States Department of Veterans Affairs is testing whether semaglutide, a medication better known for treating diabetes and obesity, can also help veterans reduce harmful drinking.
The new national trial will involve VA medical centers in 13 states. Veterans with moderate or severe alcohol use disorder will receive either semaglutide or a placebo, allowing researchers to measure changes in drinking, physical health and quality of life.
Recruitment began on July 28, 2026. The study will take several years to complete, so it does not provide a new treatment option yet. It does, however, mark one of the largest efforts so far to test a GLP-1 medication against alcohol addiction in a controlled clinical setting.
The United States Department of Veterans Affairs says more than 400,000 veterans in its healthcare system have been diagnosed with alcohol use disorder.
What The VA Is Testing?
The trial is formally called the Cessation or Reduction of Alcohol Consumption in Veterans study, shortened to CRAVE.
Participants will be randomly assigned to receive semaglutide or an inactive placebo. Neither the participants nor the clinicians working directly with them will know which treatment they received during the study.
That design gives researchers a clearer way to determine whether any reduction in drinking comes from the medication rather than expectations, additional medical attention or changes participants make after entering the trial.
| Trial Detail | Current Information |
|---|---|
| Study name | CRAVE |
| Medication | Semaglutide |
| Condition | Moderate or severe alcohol use disorder |
| Study locations | 18 VA medical centers |
| States represented | 13 |
| Eligible ages | 18 to 80 |
| Maximum weekly dose | 2.4 milligrams |
| Comparison group | Placebo injection |
| Recruitment began | July 28, 2026 |
The United States Department of Veterans Affairs announcement says more than 600 veterans are expected to take part across the participating medical centers.
The federal trial record provides a more specific target for the randomized stage. It says researchers plan to assign 438 eligible veterans equally between the semaglutide and placebo groups. The larger figure may include people screened before final enrollment and randomization.
Why A Weight-Loss Drug Is Being Studied For Alcohol Use?
View this post on Instagram
Semaglutide is part of a group of medications called GLP-1 receptor agonists. The drugs help regulate blood sugar, slow digestion and reduce appetite.
Researchers have become interested in another possible effect. GLP-1 medications may influence reward signals in the brain, including signals involved in cravings and repeated substance use.
People do not drink only because they are hungry or thirsty. Alcohol can produce a strong reward response that encourages repeated consumption, even after drinking begins to damage health, relationships or work.
The VA trial will test whether semaglutide can weaken that response enough to reduce risky drinking.
Earlier studies and patient records have produced encouraging signs, but they do not settle the question. A person taking semaglutide for diabetes or obesity may differ from another patient in many ways, including diet, medical supervision and motivation to improve health.
A randomized trial is needed to show if the medication itself makes a meaningful difference.
How The CRAVE Trial Will Work?
The federal clinical trial record describes CRAVE as a Phase 3, randomized, double-blind study.
Participants assigned to semaglutide will begin with a low dose. The amount will gradually increase, depending on how well each person tolerates the medication, to a maximum of 2.4 milligrams per week.
The placebo group will use an injection device designed to look and operate like the semaglutide pen.
Researchers will meet with participants regularly and assess their alcohol consumption, heavy-drinking days, health and treatment side effects. The main measure will be the reduction of drinking considered risky under established health guidelines.
The study record describes 28 weeks of treatment, including an initial four-week dose-increase period and a 24-week period used to measure the main results. A further four weeks will be used for post-treatment safety monitoring.
Where The Trial Is Taking Place?
The participating VA medical centers stretch from California to North Carolina, giving the research team access to veterans from several regions.
| State | Participating Area |
|---|---|
| California | Long Beach, Los Angeles and Palo Alto |
| Florida | Orlando |
| Georgia | Atlanta area |
| Illinois | Hines |
| Michigan | Ann Arbor |
| Minnesota | Minneapolis |
| North Carolina | Asheville and Durham |
| Ohio | Cleveland |
| Oregon | Portland |
| Pennsylvania | Philadelphia |
| Texas | Dallas and Houston |
| Utah | Salt Lake City |
| Washington | Seattle |
| Wisconsin | Madison |
Veterans interested in participating cannot simply request semaglutide from a regular VA appointment. They must contact a participating center, complete the screening process and meet the study requirements.
Alcohol Use Disorder Is A Major Veterans Health Issue
Alcohol use disorder is diagnosed when drinking becomes difficult to control and continues despite harmful consequences.
A person may repeatedly drink more than intended, fail to cut down, experience strong cravings or continue drinking after alcohol begins to affect health and family life. Severe cases can involve physical dependence and dangerous withdrawal symptoms.
Veterans are not one uniform group, and military service alone does not explain alcohol addiction. Drinking problems can overlap with post-traumatic stress, depression, chronic pain, sleep problems, isolation and difficulty returning to civilian life.
Those conditions can reinforce one another. Alcohol may initially appear to reduce anxiety or help a person sleep, but regular heavy use often worsens mood, sleep quality and physical health.
Our team at NCHStats has previously examined mental health among veterans, including the ways PTSD, substance use and suicide risk can overlap.
Alcohol also remains a broader public health problem across the country. State-level patterns show large differences in binge drinking and alcohol-related deaths, as detailed in our analysis of the states with the highest alcohol misuse rates.
Semaglutide Is Not Yet An Alcohol Treatment
The launch of the trial does not mean semaglutide has been approved for alcohol use disorder.
The medication is already prescribed under approved indications for diabetes and chronic weight management. Using it to treat alcohol addiction remains experimental.
The United States Department of Veterans Affairs has specifically warned veterans against self-medicating or replacing an existing treatment with a GLP-1 drug.
Semaglutide can cause nausea, vomiting, diarrhea, constipation and abdominal discomfort. Some people also face more serious risks that must be considered by a clinician.
A veteran who already takes semaglutide should not increase the dose or change the treatment schedule in an attempt to drink less.
Veterans Already Have Other Treatment Options
Veterans struggling with alcohol do not need to wait for the CRAVE results before seeking care.
Current treatment can include counseling, structured behavioral therapy, peer support and medications already used for alcohol use disorder. Depending on the patient, those medications may include naltrexone, acamprosate or disulfiram.
Some patients can be treated through regular outpatient visits. Others need medically supervised withdrawal, residential care or treatment that also addresses PTSD, depression or chronic pain.
Recovery does not always follow a straight line. A treatment that failed once may work differently when combined with another medication, therapist or level of support.
Access remains a serious national problem. Millions of Americans report needing mental health or substance-use care but do not receive it, a gap covered in our report on unmet mental health treatment needs.
The Trial Comes As VA Healthcare Enrollment Grows
The semaglutide study begins during a year of rapid growth in VA healthcare enrollment.
The United States Department of Veterans Affairs reported in July that more than 200,000 veterans had enrolled in its healthcare system since the beginning of 2026.
Those new enrollees had already generated more than 500,000 completed or scheduled healthcare encounters, including over 60,000 mental health appointments and more than 2,100 emergency-care visits.
The figures do not show how many newly enrolled veterans have alcohol use disorder. They do show that demand for VA medical and mental health services remains substantial.
Veterans who are unsure about their access to care can check the current VA healthcare eligibility requirements.
What Researchers Need To Find Out?
The most obvious question is whether veterans receiving semaglutide drink less than those receiving the placebo.
Researchers will also need to establish how large that reduction is and if it improves everyday health. A small statistical change would carry less weight than a clear decline in heavy-drinking days, hospital visits or alcohol-related problems.
Side effects will be equally important. A medication can work in theory but have limited value if many patients cannot tolerate the dose.
The study must also show which veterans benefit. Semaglutide may work better for certain groups or may prove useful only when combined with counseling and other treatment.
Cost could become another issue if the results are positive. GLP-1 drugs are expensive, and treating hundreds of thousands of eligible patients would require a major financial commitment.
The Bottom Line
Recruitment is expected to take place over an extended period, followed by months of treatment and safety monitoring for each participant. The trial record estimates that recruitment alone could continue for about 32 months.
That means a final answer is unlikely soon.
The importance of the study lies in its scale and design. Smaller studies have suggested that GLP-1 drugs may reduce alcohol cravings or drinking, but CRAVE is intended to test that possibility across hundreds of veterans under controlled conditions.
A positive result would not make semaglutide a cure for addiction. It could give doctors another tool for patients who have not improved enough with existing treatment.
For the more than 400,000 veterans already diagnosed with alcohol use disorder, another effective option could make a real difference.
